CompletedPhase 3NCT05136170
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Studying Medullary sponge kidney
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dompé Farmaceutici S.p.A
- Principal Investigator
- Flavio Mantelli, MDDompé Farmaceutici
- Intervention
- Cenegermin(drug)
- Enrollment
- 85 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2023
Study locations (10)
- Lugene Eye Institute - Glendale Office, Glendale, California, United States
- The Johns Hopkins University, Baltimore, Maryland, United States
- Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center, Boston, Massachusetts, United States
- OCLI (Ophthalmic Consultants of Long Island), Garden City, New York, United States
- Scheie Eye Institute, Philadelphia, Pennsylvania, United States
- Houston Eye Associates HEA - Gramercy Location, Houston, Tennessee, United States
- Toyos Clinic - Nashville, Nashville, Tennessee, United States
- AOU Gaspare Rodolico - Ospedale San Marco, Catania, Italy
- Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica, Milan, Italy
- AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica, Roma, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05136170 on ClinicalTrials.govOther trials for Medullary sponge kidney
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07489131Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaAlvotech Swiss AG
- RECRUITINGPHASE2NCT07441642A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationNovartis Pharmaceuticals
- ENROLLING BY INVITATIONPHASE2NCT07395986A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07400965Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisGlaukos Corporation
- RECRUITINGPHASE3NCT07235085A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyOcular Therapeutix, Inc.
- RECRUITINGPHASE2NCT07128628A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseBausch & Lomb Incorporated
- RECRUITINGPHASE3NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKKodiak Sciences Inc
- RECRUITINGPHASE3NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics